What's at stake: Hale Animal Health wants to be one of the first in the world to register cannabis pet medicines with growing global markets for animal health and cannabis products.
Background: Leila de Koster set up up Hale in 2020 with investment from Helius Therapeutics but they parted ways. New investment will help fund clinical studies required for regulatory approval.
Main players: Hale Animal Health, WNT Ventures
Hale Animal Health, which hopes to be among the first in the world to register pet medicines containing cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), is raising $2 million in a seed round.
The round is being led by WNT Ventures and includes a $750,000 loan under Callaghan Innovation’s
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
What's at stake: Hale Animal Health wants to be one of the first in the world to register cannabis pet medicines with growing global markets for animal health and cannabis products.
Background: Leila de Koster set up up Hale in 2020 with investment from Helius Therapeutics but they parted ways. New investment will help fund clinical studies required for regulatory approval.
